Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 420-1111 boul. Dr.-Frederik-Philips MONTREAL QC H4M 2X6 |
Tel: | 1-212-6001902 |
Website: | https://www.milestonepharma.com |
IR: | See website |
Key People | ||
Joseph Oliveto President, Chief Executive Officer, Director | Amit Hasija Chief Financial Officer, Executive Vice President of Corporate Development | Jeffrey Nelson Chief Operating Officer |
David Bharucha Chief Medical Officer | Lorenz Muller Chief Commercial Officer |
Business Overview |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications. |
Financial Overview |
For the fiscal year ended 31 December 2023, Milestone Pharmaceuticals Inc revenues decreased 80% to $1M. Net loss increased 2% to $59.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Commercial activities increase of 77% to $13.7M (expense), Stock-based Compensation in SGA increase of 15% to $4.8M (expense). |
Employees: | 47 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $74.12M as of Mar 31, 2024 |
Annual revenue (TTM): | $1.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$61.01M as of Mar 31, 2024 |
Net annual income (TTM): | -$59.69M as of Mar 31, 2024 |
Free cash flow (TTM): | -$46.54M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 53,149,778 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |